{"success":true,"data":{"pressRelease":{"id":"182449","rtpr_id":"nGNXtjyjf-20261028","ticker":"QURE","exchange":"NASDAQ","all_tickers":["QURE","UQ1"],"title":"uniQure to Announce Third Quarter 2026 Financial Results","author":"Globe Newswire","published_at":"2026-10-28T11:05:00.115Z","article_body":"LEXINGTON, Mass. and AMSTERDAM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- uniQure\n(https://www.globenewswire.com/Tracker?data=xVVa_RGZLkNIfdTxldotCLgZTytU7eS0fakrbSLZa2Lg3T48MnArsTNipY-3sQAi0nmSqNmX1xC1OSi3O9x7wg==)\nN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative\ntherapies for patients with severe medical needs will report third quarter\n2026 financial results before market open on Wednesday, November 4, 2026.\nManagement will then host a conference call at 8:30 a.m. ET.\n\nThe event will be webcast under the Events & Presentations section of\nuniQure’s website at\nhttps://www.uniqure.com/investors-media/events-presentations, and following\nthe event a replay will be archived for 90 days. Analysts wishing to\nparticipate in the question and answer session should access the live call by\ndialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID\n5075555. If you are joining the conference call, please join 15 minutes before\nthe start time.\n\nAbout uniQure\n\nuniQure is delivering on the promise of gene therapy – single treatments\nwith potentially curative results. The approvals of uniQure’s gene therapy\nfor hemophilia B – an historic achievement based on more than a decade of\nresearch and clinical development – represent a major milestone in the field\nof genomic medicine and ushers in a new treatment approach for patients living\nwith hemophilia. uniQure is now advancing a pipeline\n(https://www.globenewswire.com/Tracker?data=9SQCGyJnFMgy86JhEN6aq0Hs7Lc6d4pMYSsfetKAuARgVoxZZKqAlZ8qQAza1cMLZ51NK0NjlUVJRihvb1zMYWWPTTN_ETe0J9sXDV9E7orkRuIoRjonKhvcHbHggA3k)\nof proprietary gene therapies for the treatment of patients with Huntington's\ndisease, refractory temporal lobe epilepsy, Fabry disease, and other severe\ndiseases. www.uniQure.com\n\nuniQure Contacts:\n\n FOR INVESTORS:        FOR MEDIA:            \n                                             \n Chiara Russo          Tom Malone            \n Direct: 781-491-4371  Direct: 339-970-7558  \n Mobile: 617-306-9137  Mobile:339-223-8541   \n c.russo@uniQure.com   t.malone@uniQure.com  \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2ba61fe2-12e5-4a01-afe1-419652b31512)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXtjyjf-20261028","title":"uniQure to Announce Third Quarter 2026 Financial Results","author":"Globe Newswire","ticker":"QURE","created":"2026-10-28T11:05:00.115Z","tickers":["QURE","UQ1"],"exchange":"NASDAQ","article_body":"LEXINGTON, Mass. and AMSTERDAM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- uniQure\n(https://www.globenewswire.com/Tracker?data=xVVa_RGZLkNIfdTxldotCLgZTytU7eS0fakrbSLZa2Lg3T48MnArsTNipY-3sQAi0nmSqNmX1xC1OSi3O9x7wg==)\nN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative\ntherapies for patients with severe medical needs will report third quarter\n2026 financial results before market open on Wednesday, November 4, 2026.\nManagement will then host a conference call at 8:30 a.m. ET.\n\nThe event will be webcast under the Events & Presentations section of\nuniQure’s website at\nhttps://www.uniqure.com/investors-media/events-presentations, and following\nthe event a replay will be archived for 90 days. Analysts wishing to\nparticipate in the question and answer session should access the live call by\ndialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID\n5075555. If you are joining the conference call, please join 15 minutes before\nthe start time.\n\nAbout uniQure\n\nuniQure is delivering on the promise of gene therapy – single treatments\nwith potentially curative results. The approvals of uniQure’s gene therapy\nfor hemophilia B – an historic achievement based on more than a decade of\nresearch and clinical development – represent a major milestone in the field\nof genomic medicine and ushers in a new treatment approach for patients living\nwith hemophilia. uniQure is now advancing a pipeline\n(https://www.globenewswire.com/Tracker?data=9SQCGyJnFMgy86JhEN6aq0Hs7Lc6d4pMYSsfetKAuARgVoxZZKqAlZ8qQAza1cMLZ51NK0NjlUVJRihvb1zMYWWPTTN_ETe0J9sXDV9E7orkRuIoRjonKhvcHbHggA3k)\nof proprietary gene therapies for the treatment of patients with Huntington's\ndisease, refractory temporal lobe epilepsy, Fabry disease, and other severe\ndiseases. www.uniQure.com\n\nuniQure Contacts:\n\n FOR INVESTORS:        FOR MEDIA:            \n                                             \n Chiara Russo          Tom Malone            \n Direct: 781-491-4371  Direct: 339-970-7558  \n Mobile: 617-306-9137  Mobile:339-223-8541   \n c.russo@uniQure.com   t.malone@uniQure.com  \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2ba61fe2-12e5-4a01-afe1-419652b31512)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-28T11:05:00.151442207Z","server_sent_at_ms":1793185500151},"received_at":"2026-10-28T11:05:00.205Z","source_url":null},"analysis":{"id":"170241","press_release_id":"182449","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"uniQure announced it will report third quarter 2026 financial results before market open on Wednesday, November 4, 2026.\n\nManagement will host a conference call at 8:30 a.m. ET the same day, with a webcast and 90-day replay available on the company's website.\n\nThe release contains no results or guidance; it is a scheduling notice only, with the company's hemophilia B gene therapy approval and pipeline (Huntington's disease, epilepsy, Fabry disease) referenced as background.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings-date notice for QURE -- set calendar reminder for Nov 4 pre-market results."},"keyFigures":{},"namedEntities":{"people":[{"name":"Chiara Russo","role":"Investor Relations contact"},{"name":"Tom Malone","role":"Media contact"}],"products":[],"companies":[{"name":"uniQure N.V.","ticker":"QURE"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine earnings-date announcement with no financial results, guidance, or pipeline data. Pure scheduling notice."},"tickerRelevance":{"others":[],"primary":"QURE"},"globalImportance":8,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"earnings-date-scheduling-only","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"uniQure announced it will report third quarter 2026 financial results before market open on Wednesday, November 4, 2026.\n\nManagement will host a conference call at 8:30 a.m. ET the same day, with a webcast and 90-day replay available on the company's website.\n\nThe release contains no results or guidance; it is a scheduling notice only, with the company's hemophilia B gene therapy approval and pipeline (Huntington's disease, epilepsy, Fabry disease) referenced as background.","key_figures":{},"named_entities":{"people":[{"name":"Chiara Russo","role":"Investor Relations contact"},{"name":"Tom Malone","role":"Media contact"}],"products":[],"companies":[{"name":"uniQure N.V.","ticker":"QURE"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-28T11:05:03.728Z","global_importance":8,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"earnings-date-scheduling-only","issuerAuthored":true}},"durationMs":3307,"modelName":"glm-5.3-flashx"}}